<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Usual doses of short-acting bronchodilators for asthma in adolescents and adults*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Usual doses of short-acting bronchodilators for asthma in adolescents and adults*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Usual doses of short-acting bronchodilators for asthma in adolescents and adults*</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug name(s)</td> <td class="subtitle1">Preparation(s)<sup>¶</sup></td> <td class="subtitle1">Dose</td> </tr> <tr> <td>Albuterol MDI<sup>Δ</sup></td> <td> <p>MDI: 90 mcg/inhalation (United States)</p> MDI: 100 mcg/inhalation (Canada)</td> <td> <ul> <li>Usual dose: 2 inhalations every 4 to 6 hours as needed</li> <li>Acute exacerbation at home: 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then as directed<sup>◊</sup></li> <li>Acute care setting: 4 to 8 inhalations every 20 minutes for 3 doses<sup>§</sup>, then taper depending on response to therapy</li> </ul> </td> </tr> <tr> <td>Albuterol DPI</td> <td>DPI<sup>Δ</sup>: 90 mcg/actuation (United States)</td> <td> <ul> <li>Usual dose: 2 inhalations every 4 to 6 hours, as needed</li> <li>Acute exacerbation at home: 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then as directed<sup>◊</sup></li> <li>Acute care setting: 4 to 8 inhalations every 20 minutes for 3 doses<sup>§</sup>, then taper depending on response to therapy</li> </ul> </td> </tr> <tr> <td>Albuterol DPI (Canada)</td> <td>DPI: 200 mcg/actuation (Canada)</td> <td> <ul> <li>Usual dose: 1 inhalation every 4 to 6 hours, as needed</li> <li>Exercise-induced bronchoconstriction: 1 inhalation 15 minutes prior to exercise</li> </ul> </td> </tr> <tr> <td>Albuterol solution for nebulization</td> <td>Nebulizer solutions: <ul class="decimal_heading"> <li>0.083% (2.5 mg/3 mL)</li> <li>0.5% (2.5 mg/0.5 mL) concentrate; must be diluted in 2.5 mL saline</li> </ul> </td> <td> <ul> <li>Usual dose: 2.5 mg every 4 to 6 hours, as needed</li> <li>Acute exacerbation at home: Administer 2.5 mg, can repeat every 20 minutes for total of 3 doses, then decrease frequency to every 1 to 4 hours, as tolerated<sup>¥</sup></li> <li>Acute care setting: Administer 2.5 to 5 mg, can repeat every 20 minutes for total of 3 doses, then decrease frequency to every 1 to 4 hours, as tolerated</li> <li>Acute care setting (critically ill): Continuous nebulizer treatment: Use a large volume nebulizer, 10 to 15 mg/hour in monitored setting</li> </ul> </td> </tr> <tr> <td>Albuterol-budesonide MDI</td> <td>MDI: Albuterol 90 mcg and budesonide 80 mcg/actuation (United States)</td> <td> <ul> <li>Usual dose: 2 inhalations every 4 to 6 hours as needed</li> <li>Acute exacerbation at home: 2 inhalations, can be repeated every 20 minutes for a total of 3 doses, then as directed<sup>¥</sup></li> </ul> </td> </tr> <tr> <td>Levalbuterol MDI<sup>Δ</sup></td> <td>45 mcg/inhalation (United States)</td> <td> <ul> <li>Usual dose: 2 inhalations every 4 to 6 hours, as needed</li> <li>Acute exacerbation at home: 2 to 4 inhalations; can be repeated every 20 minutes for a total of 3 doses, then as directed<sup>◊</sup></li> <li>Acute care setting: 4 to 8 inhalations every 20 minutes for 3 doses, then taper depending on response to therapy<sup>§</sup></li> </ul> </td> </tr> <tr> <td>Levalbuterol solution for nebulization</td> <td>Nebulizer solution: <ul class="decimal_heading"> <li>0.63 mg/3 mL</li> <li>1.25 mg/3 mL</li> <li>1.25 mg/0.5 mL concentrate; must be diluted in 2.5 mL saline</li> </ul> </td> <td> <ul> <li>Usual dose: Administer 0.63 to 1.25 mg (equivalent to 1.25 to 2.5 mg albuterol) every 6 to 8 hours, as needed (up to 3 doses per 24 hours)</li> <li>Acute exacerbation at home: Administer 1.25 mg; can be repeated every 20 minutes for a total of 3 doses, then decrease frequency to every 1 to 4 hours, as tolerated<sup>¥</sup></li> <li>Acute care setting: Administer 1.25 mg to 2.5 mg (equivalent to 2.5 to 5 mg of albuterol); can repeat every 20 minutes for total of 3 doses, then decrease frequency to every 1 to 4 hours, as tolerated</li> </ul> </td> </tr> <tr> <td>Terbutaline DPI</td> <td>DPI: 0.5 mg/actuation (Canada)</td> <td> <ul> <li>Usual dose: 1 inhalation every 4 hours, as needed</li> <li>If no effect after 5 minutes, can repeat dose</li> </ul> </td> </tr> <tr> <td>Ipratropium-albuterol SMI</td> <td>SMI: Ipratropium 20 mcg and albuterol 100 mcg/inhalation (United States)</td> <td> <ul> <li>Usual dose (off-label): 2 inhalations every 6 hours, as needed</li> <li>Acute exacerbation (off-label): 4 to 8 inhalations every 20 minutes for 3 doses, and then as needed for up to 3 hours</li> </ul> </td> </tr> <tr> <td>Ipratropium-albuterol solution for nebulization</td> <td>Nebulizer solution: Ipratropium 0.5 mg and albuterol 2.5 mg per 3 mL/vial<sup>‡</sup></td> <td> <ul> <li>Usual dose (off-label): Administer 1 vial (3 mL) every 4 to 6 hours, as needed</li> <li>Acute exacerbation (off-label): Administer 1 vial (3 mL), every 20 minutes for 3 doses, and then as needed for up to 3 hours<sup>¥</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>MDI: metered-dose inhaler; DPI: dry-powder inhaler; SMI: soft mist inhaler.</p>
<p>* Oral formulations of albuterol and terbutaline are less effective than inhaled formulations and are not recommended in asthma. Inhaled epinephrine (MDI or nebulized) is not recommended for routine use.</p>
<p>¶ Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States and Canada as noted, which may differ from how strengths are described for products available in other countries. Consult local product information before use.</p>
<p>Δ Agent can also be used to prevent exercise-induced bronchoconstriction, 2 inhalations 5 to 20 minutes prior to exercise.</p>
<p>◊ Typically, two puffs are used for mild-to-moderate symptoms and four puffs for more severe symptoms; over the course of the first hour, the patient can determine (based on action plan or clinician guidance) whether to continue self-care at home or seek additional medical attention.</p>
<p>§ The number of inhalations is based on the severity of respiratory impairment, number of inhalations the patient has already used, and availability of monitoring. When administering an albuterol MDI for acute asthma exacerbation in an office or acute care setting, use of a valved holding chamber and careful attention to technique are recommended.</p>
<p>¥ Over the course of the first hour, the patient can determine (based on action plan or clinician guidance) whether to continue self-care at home or seek additional medical attention.</p>
‡ Nebulizer solution in Canada is ipratropium 0.5 mg and albuterol 2.5 mg per 2.5 mL.</div><div id="graphicVersion">Graphic 72467 Version 27.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
